At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Aug 4, 2026 at 05:00 ET
SRX Global Inc. (SRXH) announced it has acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage biopharma company. SRX views VTGN shares as undervalued and signaled openness to constructive engagement with Vistagen's leadership to discuss unlocking shareholder value. This is a small-cap activist-style investment by SRX, not a full acquisition, and the stake size and price were not disclosed.
- SRX Global acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage biopharma company.
- SRX views VTGN shares as undervalued and welcomes constructive engagement with Vistagen's leadership and Board.
- The size of the stake, purchase price, and percentage ownership were not disclosed.
- SRX describes itself as an AI-enabled platform investing in high-conviction operating companies and strategic assets.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access